Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.

doi:10.1136/gutjnl-2019-319970

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.

Gut - 1 Apr 2021

Gout Johann, Perkhofer Lukas, Morawe Mareen, Arnold Frank, Ihle Michaela, Biber Stephanie, Lange Sebastian, Roger Elodie, Kraus Johann M, Stifter Katja, Hahn Stephan A, Zamperone Andrea, Engleitner Thomas, Müller Martin, Walter Karolin, Rodriguez-Aznar Eva, Sainz Bruno, Hermann Patrick C, Hessmann Elisabeth, Müller Sebastian, Azoitei Ninel, Lechel André, Liebau Stefan, Wagner Martin, Simeone Diane M, Kestler Hans A, Seufferlein Thomas, Wiesmüller Lisa, Rad Roland, Frappart Pierre-Olivier, Kleger Alexander

Abstract excerpt

OBJECTIVE: ATM serine/threonine kinase (ATM) is the most frequently mutated DNA damage response gene, involved in homologous recombination (HR), in pancreatic ductal adenocarcinoma (PDAC). DESIGN: Combinational synergy screening was performed to endeavour a genotype-tailored targeted therapy. RESULTS: Synergy was found on inhibition of PARP, ATR and DNA-PKcs (PAD) leading to synthetic lethality in ATM-deficient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ataxia Telangiectasia Mutated Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Pancreatic Ductal

Share to Drug Resistance, Multiple

Share to Drug Synergism

Share to Epithelial-Mesenchymal Transition

Share to Homologous Recombination

Share to Pancreatic Neoplasms

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32873698
DOI: 10.1136/gutjnl-2019-319970
PMCID: PMC7948173

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic targeting and resistance to PARP inhibition in DNA damage repair-deficient pancreatic cancer.PMID 32873698Read ↗

ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA DamageSemantic proximity Read ↗

ATM Dysfunction in Pancreatic Adenocarcinoma and Associated Therapeutic Implications.Semantic proximity Read ↗

Targeting DNA Damage Repair Mechanisms in Pancreas CancerSemantic proximity Read ↗

Combination of PARP and KRASG12D inhibitors enhances therapeutic efficacy by exploiting vulnerabilities in PDAC.Semantic proximity Read ↗

Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for PracticeSemantic proximity Read ↗

Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP InhibitionSemantic proximity Read ↗

Targeting the DNA damage response protein ATR kinase in pancreatic cancerSemantic proximity Read ↗

Sequential ATR and PARP Inhibition Overcomes Acquired DNA Damaging Agent Resistance in Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectivesSemantic proximity Read ↗

BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future ProspectsSemantic proximity Read ↗

DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.Semantic proximity Read ↗

Targeted CRISPR screening identifies PRMT5 as synthetic lethality combinatorial target with gemcitabine in pancreatic cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.